Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs. Lilly sells the compound tirzepatide under two different names -- Mounjaro for type 2 diabetes and Zepbound for weight loss.

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy. Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation,

Prime Minister Keir Starmer said weight-loss drugs like Novo Nordisk’s Ozempic and Eli Lilly and Co’s Mounjaro could help improve the UK economy and lift pressures on the country’s beleaguered National Health Service,